The clinical efficiency of Mastodinon (Bionorica) is studied in management of 33 patients (average age 34,6 years) with different menstrual disfunctions and dysmenorrhea. In 13 patients these disturbances coexisted with hyperprolactinemia. As a result of 3-month treatment with Mastodinon we noted the normalization of menstrual function in 13 of 17 patients, and the decrease in prolactin serum levels on 10 of 13 women. The prolactin decrease was followed by increase in luteinizing hormone and progesteron, as chosen for ovulatory cycle. It is found that Mastodinon has the properties of dopaminomimetics and can be concerned as the alternative for synthetic dopaminergic drug therapy (Bromocriptine etc.).

At 75 patients (average age 57,2 years, average postmenopausal period 3,5 years) the hormonal replacement therapy is carried out because of climacteric syndrome with Proginova (29 women), Cyclo-Proginova (25 women) and Climen (21 women). The preparations were nominated in a cyclic mode (average duration of treatment has made 5,6 cycles). There is marked a high therapeutic effect as reduction of frequency of vegetovascular climacteric frustrations in Proginova application (83 % ), Cyclo- Proginova (84 %) and Climen (96%). The application of Proginova, Cyclo-Proginova and Climen resulted in normalization of lipid spectrum of blood by 3 month of treatment, that was expressed in authentic decrease in initially raised cholesterin and cholesterin of low density, with increase of the contents of cholesterin fraction of high density. The marked normalization of lipid spectrum as a result of hormonal replacement therapy can be considered as pathogenic influence directed on normalization in age - associated metabolic infringements in female organism.